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Abstract: Polyunsaturated fatty acids (PUFA) correlate with risk of dyslipidemia and cardiovascular
diseases. Fatty acid desaturase (FADS) single nucleotide polymorphisms (SNPs) modulate circulating
PUFA concentrations. This study examined influence of FADS1 and FADS2 genetic variants
on desaturase activities and blood lipid concentrations in type 2 diabetes patients, and further
assessed their interrelationships. Selected SNPs (FADS1: rs174547, rs174548, rs174550; FADS2:
rs174575, rs174576, rs174583, rs498793 and rs2727270) were genotyped in 820 type 2 diabetes patients
and compared with those reported in the HapMap. Patient subgroups (n = 176) without taking
lipid-lowering medicine were studied to assess influence of tag SNPs including rs174547, rs174575,
rs498793 and rs2727270 on delta-5 desaturase (D5D: 20:4 (n-6)/20:3 (n-6)) and delta-6 desaturase
(D6D:18:3 (n-6)/18:2 (n-6)) activities, and blood lipids. FADS1 rs174547 TT/TC/CC and FADS2
rs2727270 CC/CT/TT were significantly (p for trend < 0.05) associated with reduced HDL-C, D5D
and D6D activities. Upon adjustment for confounders, D5D (p = 0.006) correlated significantly and
D6D marginally (p = 0.07) correlated with increased HDL-C levels, whereas rs174547 and rs2727270
polymorphisms were not associated. D6D andD5D activities may play a role in modulating HDL-C
levels in type 2 diabetes. Future studies with larger sample sizes are needed to investigate how FADS
genetic variations interact with desaturase activities or PUFAs in the metabolism of lipoproteins in
diabetic patients.
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1. Introduction
Type 2 diabetes mellitus is a well-established risk factor for cardiovascular diseases, and is
frequently accompanied by metabolic abnormalities including hypertriglyceridemia, high low-density
lipoprotein cholesterol (LDL-C) or low high-density lipoprotein cholesterol (HDL-C) [1,2]. Recent
studies have implicated a role of raising HDL-C for the prevention and management of diabetes [2,3].
Adults with diabetes have heart disease-related mortality rates that are two to four times higher than
those without diabetes [4]. It is, therefore, important to study risk factors for the development of
dyslipidemia in patients with type 2 diabetes.
Fatty acid desaturase 1 (FADS1) and fatty acid desaturase 2 (FADS2) genes are located closely on
chromosome 11 (11q12–13.1) [5] and encode delta-5 desaturase (D5D) and delta-6 desaturase (D6D)
to [6] serve as rate limiting enzymes for catalyzing the formation of double bonds at delta-5 and delta-6
positions in n-6 or n-3 long chain polyunsaturated fatty acids (PUFA), respectively [7]. Recent gene
and genome-wide association studies (GWAS) have shown that polymorphisms in the FADS gene
cluster have an important impact on lipid profiles and glucose homeostasis, [8–10] and thus they play
a role in modifying risk of metabolic diseases.
Two recent genome wide association studies have also associated several common variants of
FADS1 and FADS2 genes with polygenic dyslipidmia [11,12]. Several studies suggested that a cluster
of SNPs including rs174547, rs174576 and rs174537are in strong linkage disequilibrium (LD) within
the FADS1-FADS2 region in Caucasian and Asian adults [13–15]. SNPs of FADS1 rs174547 or FADS2
rs174576 have been correlated with LDL-C [10], HDL-C [11,14] and triglyceride [14]. Furthermore,
these polymorphisms also have been shown to modulate D5D and D6D activities, further leading to
changes in n-3/n-6 PUFA status [16,17] in healthy adults of different ethnicities.
FADS genotypes and desaturase indices have been implicated in insulin resistance [18] and
heart diseases [19]. To date, the influences of common FADS genetic variants on desaturase activities
and blood lipids profile have only been studied in healthy adults of Caucasian or Asian origin,
and little research has been undertaken in individuals with diabetes. In this study, we genotyped SNPs
(FADS1: rs174547, rs174548, rs174550; FADS2: rs174575, rs174576, rs174583, rs498793 and rs2727270)
in 820 patients with type 2 diabetes and compared our findings with those reported in HapMap in
a healthy population. We further assessed influence of tag SNPs including rs174547, rs174575, rs498793
and rs2727270 on D5D and D6D activities and blood lipids in a subgroup (n = 176) who were not
recorded as receiving lipid lowering drugs on medical records.
2. Subjects and Methods
2.1. Study Subjects and Inclusion Criteria
We enrolled type 2 diabetes patients who participated in the diabetes management through
an integrated delivery system (DMIDS) (ClinicalTrials.gov NCT00288678). Patients between 30 and
70 years old who had been diagnosed or newly diagnosed as having type 2 diabetes by their physicians
of primary healthcare clinics based on criteria established by the American Diabetes Association
(ADA) were recruited [20]. Pregnant women and participants with a history of myocardial infarction,
cerebrovascular accident (e.g., stroke), foot amputation, and uremia under dialysis were excluded at
baseline recruitment. The protocol of the study has been described previously [21]. Briefly, 1209 newly
diagnosed type 2 diabetes patients were recruited between August 2003 and December 2005. Of those
patients, 874 completed the follow-up through the end of 2009. We only included 820 participants
who had available DNA collected in year of 2008 for the genotyping that we performed in this study.
Furthermore, we selected 176 diabetes patients who, according to their medical records, had not used
lipid-lowering drugs (statin and fibrate) and had complete plasma fatty acid workups to examine the
associations of concentrations of fatty acids with different polymorphisms of FADS. The protocol of this
study was approved by the Ethics Committee of the National Health Research Institutes and Kaohsiung
Medical University Hospital, Taiwan. Each subject signed an informed written consent form.
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2.2. Clinical Data Collection and Measurements
Trained research assistants or nurses measured height, weight, as well as systolic and diastolic
blood pressure. Venous blood was collected after overnight fasting for at least 8 h for hematological
analysis. All blood samples were stored at 2–8 ◦C and delivered to a central laboratory certified by the
College of American Pathology and US Commission on Office Laboratory Accreditation. Glycated
hemoglobin (HbA1c) was assessed by high-performance liquid chromatography (Variant II; Bio-Rad
Laboratories, Hercules, CA, USA). Levels of plasma blood glucose, triglycerides, cholesterol, LDL-C,
HDL-C, and serum creatinine were measured by an automatic analyzer (Hitachi 7060; Hitachi High
Technologies, Tokyo, Japan).
2.3. Gas Chromatography Analysis of Plasma Lipids
Extraction of plasma lipids was based on a method described by Bligh and Dyer [22]. Extracted
lipids were derivatized to fatty acid methyl esters using boron trifluoride-methanol. These were
quantified by gas chromatography (6890 N GC system, Agilent Technologies, Santa Clara, CA, USA).
The gas chromatographer was equipped with a Agilent J&W DB-225 capillary column (30 m× 0.25 mm
inner diameter × 0.25 mm film) with N2 being employed as the carrier gas. Fatty acids levels were
measured using C17:0 (Sigma, St. Louis, MO, USA) as internal standard and fatty acid concentrations
were expressed as a percentage of total area under the peaks (weight %) [23].
2.4. Measurements of Desaturase and Pathway Activities
Desaturase and pathway activities were evaluated by ratios of product/precursor fatty acids.
Desaturase activities for D6D and D5D were as follows: D6D activity = [18:3 (n-6)/18:2 (n-6)] and D5D
activity = [20:4 (n-6)/20:3 (n-6)] [24]. Pathway activities were as follows: n-3 pathway = [20:5 (n-3)/18:3
(n-3)] and n-6 pathway = [20:4 (n-6)/18:2 (n-6)] [15].
2.5. SNP Selection and Genotyping
FADS1 SNPs (rs174547, rs174548, rs174550) and FADS2 SNPs (rs174575, rs174576, rs174583,
rs498793 and rs2727270) were chosen based on findings of previous studies [10,11,15]. Four of the
SNPs including rs174547, rs174575, rs2727270 and rs498793were tag SNPs with minor allele frequencies
(MAF) >5% and were reported in the HapMap of the Han Chinese healthy population. Pairwise |D’|
and r2 values between SNPs were computed using Haploview version 4.2 (Broad Institute, Cambridge,
MA, USA). The four SNPs (rs174548, rs174550, rs174576, and rs174583) were genotyped in our study
and found to be highly correlated with the tag SNP (rs174547) (r2 ≥ 0.9). Thus, only the results for the
tag SNP (rs174547) are presented.
FADS SNP genotyping was analyzed by the GenomeLabTM SNPstream® genotyping platform
(Beckman Coulter Inc., Fullerton, CA, USA) and its accompanying SNPstream software suite were
used to perform multiplex polymerase chain reaction (12-plex PCR) and SNP genotyping by methods
previously described [25]. Primers were designed to amplify DNA, and probes designed to identify
the SNPs. Ten percent of the samples were duplicated, masked and tested twice. All SNPs were found
to be accurately genotyped at a rate of >95%.
2.6. Statistical Analysis
All statistical operations were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
The normality of the continuous variables was performed using Kolmogorov-Smirnov test. If data were
not normally distributed, parameters were transformed logarithmically before analysis. Biochemical
data among the FADS1 and FADS2 SNP genotypes were compared for significance using independent
t-test and analysis of variance (ANOVA). Simple linear regression analysis was used to evaluate the
trend among FADS SNP genotypes (p for trend). Multiple linear regression analysis was used to
evaluate independent associations among FADS polymorphisms, desaturase (D5D and D6D) activities
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and blood lipids levels by adjusting for confounding factors (age, gender, body mass index, education
(≤6 year, >6 year), and diabetes duration (years), HbA1c, alcohol use (yes, no) and exercise (yes, no)).
We used the Haploview version 4.2 (Broad Institute, Cambridge, MA, USA) to calculate the pairwise
|D’| and r2 values between SNPs. All statistical results were considered significant at p value < 0.05 in
a two-sided test.
3. Result
3.1. General Characteristics of Type 2 Diabetes Patients
The distributions of demographic and clinical characteristics of all type 2 diabetes patients
(n = 820) and those who did not use lipid-lowering drugs (n = 176) are summarized in Table 1. The mean
age of the subjects was 59.5 years old and average diabetes duration was 11.0 years. A little more than
half (52.6%, n = 431) were female.
Table 1. Baseline characteristics of 820 type 2 diabetes patients and those who without using
lipid-lowering drugs (n = 176) a.
Variables All Type 2 Diabetes Patients(n = 820)
Type 2 Diabetes Patients without Using
Lipid-Lowering Drugs (n = 176) b
Clinical Measures
Age (year) 59.5 ± 8.5 58.3 ± 8.9
Female (%) 431 (52.6) 99 (56.3)
Diabetes duration (year) 11.0 ± 5.7 10.7 ± 5.3
Education ≤6 years (%) 446 (54.4) 90 (51.1)
Smoking (%) 243 (29.6) 47 (26.7)
Drinking (%) 99 (12.1) 21 (11.9)
Exercise (%) 529 (64.5) 108 (61.4)
Body mass index (kg/m2) 26.1 ± 3.8 25.4 ± 3.9
Systolic blood pressure (mmHg) 136.4 ± 19.6 135.5 ± 22.6
Diastolic blood pressure (mmHg) 79.4 ± 11.0 79.1 ± 11.3
Triglyceride (mmol/L) 1.8 ± 1.1 1.6 ± 1.1
Cholesterol (mmol/L) 4.9 ± 0.9 4.8 ± 0.9
LDL-C (mmol/L) 3.1 ± 0.8 3.0 ± 0.8
HDL-C (mmol/L) 1.0 ± 0.3 1.0 ± 0.3
non-HDL-C (mmol/L) 3.9 ± 0.8 3.8 ± 0.9
Fasting glucose (mmol/L) 8.3 ±2.7 8.7 ± 3.0
Hemoglobin A1c (%) 8.0 ± 1.5 8.2 ± 1.6
Serum creatinine (µmol/L) 86.6 ± 67.7 80.7 ± 63.2
Blood urea nitrogen (mmol/L) 5.8 ± 2.8 5.3 ± 2.3
Plasma PUFA (%) c
Total PUFA 40.5 ± 3.5
n-3 PUFA 6.9 ± 2.2
C18:3 n3 (alpha-linolenic acid) 0.9 ± 0.3
C20:5 n3 (eicosapentaenoic acid) 0.9 ± 0.7
n-6 PUFA 33.6 ± 3.6
C18:2 n6 (linoleic acid) 24.1 ± 4.1
C18:3 n6 0.2 ± 0.2
C20:3 n6 1.7 ± 0.5
C20:4 n6 (arachidonic acid) 6.6±1.6
Abbreviations: LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol. PUFA,
polyunsaturated fatty acids; a Data presented was mean ± SD or n (%). b 176 type 2 diabetes patients without
using lowering lipid drugs (statin and fibrate) and with complete plasma fatty acid measures were selected. c Only
selected n-6 and n-3 PUFA were presented.
3.2. Genotype and Allele Distribution of FADS1 and FADS2 Polymorphisms among All Type 2
Diabetes Patients
Table 2 shows the distributions of genotype and allele frequencies of the eight selected SNPs in
diabetes patients. None of the genotype distributions in our study were differed significantly from
those expected under Hardy-Weinberg equilibrium (HWE), except for rs498793. For all SNPs examined
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in our diabetic subjects, the frequencies of genotypes, rs174547, rs174548, rs174576, rs174583 and
rs498793, were comparable to those reported in the HapMap CHD (Chinese in Metropolitan Denver,
CO, USA) population.
Table 2. Genotype and allele distribution of FADS polymorphisms among 820 type 2 diabetes patients a.
Gene SNPs Alleles(Major/Minor)
Genotype
(MM/Mm/mm)
Allele Frequency
(M/m)
Hapmap Genotype
Frequency b
(Allele Frequency)
HWE
(p Value) e
FADS1 rs174547 T/C
280/395/145 955/685 33.3/41.7/25.0 c
0.774(34.1/48.2/17.7) (58.2/41.8) (54.2/45.8) c
FADS1 rs174548 G/C
268/404/147 940/698 31.8/41.2/27.1 c
0.806(32.7/49.3/17.9) (57.4/42.6) (52.4/47.6) c
FADS1 rs174550 C/T
278/397/145 953/687 45.5/40.9/13.6 d
0.874(33.9/48.4/17.7) (41.9/58.1) (65.9/34.1) d
FADS2 rs174575 C/G
613/188/19 1414/226 80.0/17.8/2.2 d
0.314(74.8/22.9/2.3) (86.2/13.8) (88.9/11.1) d
FADS2 rs174576 A/C
280/397/143 957/683 31.8/43.5/24.7 c
0.911(34.1/48.1/17.4) (58.3/41.7) (53.5/46.5) c
FADS2 rs174583 T/C
280/396/142 956/680 32.1/44/0/23.8 c
0.922(34.1/48.3/17.3) (58.4/42.6) (54.2/45.8) c
FADS2 rs498793 G/A
683/124/13 1490/150 79.8/20.2/0 c
0.010(83.3/15.1/1.6) (90.9/9.1) (89.9/10.1) c
FADS2 rs2727270 C/T
243/421/156 907/733 65.1/25.6/9.3 d
0.270(29.6/51.3/19.0) (55.3/44.7) (77.9/22.1) d
Abbreviations: SNP, single nucleotide polymorphism; M, major allele; m, minor allele. a Data is presented as n (%).
b The Hapmap website (http://www.ncbi.nlm.nih.gov.) provides human genome information based on a general
healthy population. c The HapMap reference was provided by Chinese in Metropolitan Denver (CHD), CO, USA.
d SNPs of rs174550, rs174575 and rs2727270 were not available from the Chinese Han population in Denver but
from Han Chinese in Beijing (HCB), China. e HWE, Hardy-Weinberg equilibrium. HWE for genotype frequency
was analyzed by Chi-squared test.
Table 3. The differences of fatty acid desaturase activities among FADS1 and FADS2 genotypes in type
2 diabetes patients (n = 176) a.
Genotypes n
D5D Activity D6D Activity n-3 Pathway Activity n-6 Pathway Activity
(20:4 n6/20:3 n6) (18:3 n6/18:2 n6) (20:5 n3/18:3 n3) (20:4 n6/18:2 n6)
Mean± SD
FADS1 TT 23 4.785 ± 1.162 0.020 ± 0.010 1.001 ±0 .297 0.389 ± 0.087
rs174547 d TC 90 4.188 ± 1.306 0.011 ± 0.006 0.947 ± 0.358 0.300 ± 0.091
CC 63 4.126 ± 1.845 0.006 ± 0.005 0.842 ± 0.987 0.233 ± 0.075
p value 0.05 <0.001 0.001 <0.001
p for trend 0.022 <0.001 <0.001 <0.001
FADS2 CC 132 4.285 ±1.503 0.011 ± 0.008 0.936 ± 0.716 0.292 ± 0.983
rs174575 d CG+GG 44 4.120 ± 1.552 0.009 ± 0.007 0.858 ± 0.407 0.266 ± 0.095
p value b 0.426 0.008 0.309 0.098
p for trend c - - - -
FADS2 GG 149 4.199 ± 1.393 0.011 ± 0.008 0.935 ± 0.678 0.291 ± 0.094
rs498793 d GA+AA 27 4.490 ± 2.069 0.008 ± 0.006 0.815 ± 0.479 0.255 ± 0.113
p value b 0.866 0.031 0.112 0.065
p for trend c - - - -
FADS2 CC 41 4.528 ± 1.300 0.015 ± 0.009 1.039 ± 0.392 0.355 ± 0.101
rs2727270 d CT 99 4.210 ± 1.477 0.011 ± 0.007 0.923 ± 0.803 0 .275 ± 0.090
TT 36 4.013 ± 1.802 0.005 ± 0.002 0.759 ± 0.321 0.232 ± 0.069
p value 0.120 <0.001 0.006 <0.001
p for trend 0.039 <0.001 0.001 <0.001
Abbreviations: FADS, fatty acid desaturase; a Data presented is mean± SD. ANOVA analysis was performed to test
the differences among the FADS SNP genotypes (p value). Simple linear regression analysis was performed to test the
trend among FADS SNP genotypes (p for trend). b Independent t-test analysis was performed to test the differences
for SNPs rs174575 and rs498793 genotypes (p value). c Simple linear regression analysis (p for trend) didn’t perform
as the genotype combined into two groups. d rs174547, rs174575, rs498793 and rs2727270 are tag SNPs.
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Table 4. Differences of plasma lipid concentrations among FADS1 and FADS2 genotypes in type 2
diabetes patients (n = 176). a
Plasma Lipids
Genotypes Triglyceride Cholesterol LDL-C HDL-C Non-HDL-C
(mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
n Mean± SD
FADS1 TT 23 1.4 ± 0.6 5.1 ± 0.9 3.3 ± 0.9 1.1 ± 0.3 4.0 ± 0.9
rs174547 d TC 90 1.6 ± 1.2 4.8 ± 0.8 3.0 ± 0.7 1.0 ± 0.2 3.8 ± 0.8
CC 63 1.7 ±1.1 4.7 ± 1.0 2.9 ± 0.9 1.0 ± 0.3 3.7 ± 0.9
p value 0.699 0.201 0.098 0.098 0.485
p for trend 0.426 0.082 0.059 0.031 0.248
FADS2 CC 132 1.5 ± 1.0 4.8 ± 0.9 3.0 ± 0.8 1.0 ± 0.3 3.8 ± 0.9
rs174575 d CG+GG 44 1.7 ± 1.3 4.9 ± 0.9 3.0 ± 0.9 1.0 ± 0.3 3.8 ± 0.9
p value b 0.625 0.645 0.983 0.964 0.627
p for trend c - - - - -
FADS2 GG 149 1.6 ± 1.2 4.9 ± 0.9 3.0 ± 0.8 1.0 ± 0.3 3.8 ± 0.9
rs498793 d GA+AA 27 1.4 ± 0.7 4.5 ± 0.9 2.8 ± 0.8 1.0 ± 0.2 3.5 ± 0.8
p value b 0.482 0.034 0.261 0.298 0.096
p for trend c - - - - -
FADS2 CC 41 1.5 ± 1.3 5.0 ± 0.9 3.1 ± 0.9 1.1 ± 0.3 3.9 ± 0.9
rs2727270 d CT 99 1.6 ± 0.9 4.8 ± 0.8 3.0 ± 0.7 1.0 ± 0.3 3.8 ± 0.8
TT 36 1.6 ± 1.3 4.6 ± 1.0 3.0 ± 1.0 1.0 ± 0.3 3.7 ± 1.0
p value 0.472 0.147 0.249 0.083 0.354
p for trend 0.699 0.059 0.112 0.025 0.299
Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol. a Data
presented is mean ± SD. ANOVA analysis was performed to test the differences among the FADS SNP genotypes
(p value). Simple linear regression analysis was performed to test the trend among FADS SNP genotypes (p for trend).
b Independent t-test analysis was performed to test the differences for SNPs rs174575 and rs498793 genotypes
(p value). c Simple linear regression analysis (p for trend) didn’t perform as the genotype combined into two groups.
d rs174547, rs174575„ rs498793 and rs2727270 are tag SNPs.
As shown in Figure 1, tag SNP rs174547 was in high LD with rs174548 (r2 = 0.96), rs174550
(r2 = 0.99), rs174576 (r2 = 0.97) and rs174583 (r2 = 0.97). Therefore, only four tag SNPs including
rs174547, rs174575, rs2727270 and rs498793 were examined for their impact on desaturase activities
(Table 3) and lipid status (Table 4).
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3.3. FADS1 and FADS2 Genotypes and D5D and D6D Activities in Type 2 Diabetes Patients
Table 3 presents the desaturase activities categorized by FADS genotypes of 176 type 2 diabetes
patients not using lipid-lowering drugs. The FADS1 rs174547 TT, TC, CC genotypes were significantly
and linearly associated with reduced D5D (P for trend = 0.022) and D6D (p for trend < 0.001) activities,
as well as with n-3 and n-6 pathway activities (both p for trend < 0.001). Similarly, FADS2 rs2727270 CC,
CT and TT genotypes were negatively correlated with D5D (p for trend = 0.039), D6D (p for trend < 0.001),
n-3 pathway (p for trend = 0.001) and n-6 pathway activities (p for trend < 0.001). Subjects carrying
rs174575 and rs498793 minor allele were quite few, so genotypes with minor allele were combined for
analysis. Subjects with rs174575 CG and GG genotypes (p = 0.008) as well as with rs498793 GA and
AA genotypes (p = 0.031) had significantly lower D6D activities.
3.4. FADS1 and FADS2 Genotypes and Lipid Traits in Type 2 Diabetes Patients
Table 4 presents the plasma lipid profiles among FADS2 genotypes in 176 type 2 diabetes patients
not using lipid-lowering drugs. The FADS1 rs174547 TT, TC, CC (p for trend = 0.031) genotypes were
negatively associated with reduced HDL-C concentrations. Similarly, FADS2 rs2727270 CC, CT and TT
(p for trend = 0.025) genotypes were negatively correlated with HDL-C levels. Frequencies of rs498793
A allele were small, so genotypes with minor allele were combined for analysis. Subjects carrying
rs498793 GA and AA genotypes (4.5 ± 0.9 mmol/L) were found to have significantly lower (p = 0.034)
cholesterol levels than those with GG genotype (4.9 ± 0.9 mmol/L). The FADS1 rs174575 did not
appear to correlate with any lipid trait.
3.5. Relations among FADS Genotypes, Desaturases Activities and HDL-C Levels
Table 5 shows the independent associations among FADS1 rs174547, FADS2 rs2727270, desaturase
activities and HDL-C concentrations in 176 diabetes patients not using statins or fibrates by multiple
linear regression analysis. After adjustment for age, gender, body mass index and diabetes duration,
HbA1c, alcohol use and exercise habit, model 5 showed that D5D correlated significantly (p = 0.006)
and D6D was marginally correlated (p = 0.07) with increased HDL-C. Whereas rs174547 and rs2727270
polymorphisms were not. We found D5D activities to correlate positively with HDL-C levels and
D6D correlate marginally. FADS1 rs174547 and FADS2 rs2727270 polymorphisms were not found to
correlate with those levels.
Table 5. Associations among FADS1 rs174547, FADS2 rs2727270, desaturases activities and HDL-C
levels type 2 diabetes using multiple linear regression analysis (n = 176). a
Model 1 Model 2 Model 3 Model 4 Model 5
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p
rs174547 −0.059(0.031) 0.056 - - -
0.006
(0.050) 0.898
rs2727270 - −0.057(0.031) 0.064 - -
−0.018
(0.045) 0.687
D5D activity - - 0.034(0.014) 0.019 -
0.041
(0.015) 0.006
D6D activity - - - 5.303(2.759) 0.056
6.239
(3.414) 0.070
Abbreviations: D5D, delta-5-desaturase; D6D, delta-6-desaturase; a All models are adjusted for confounding factors
including age, gender, body mass index, education (≤6 y, >6 y), diabetes duration (years), hemoglobinA1c, alcohol
use (yes, no) and exercise (yes, no).
4. Discussion
This study found FADS1 rs174547 and FADS2 rs2727270 genotypes were significantly correlated
with decreased D5D and D6D activities and decreased HDL-C concentrations in patients with type 2
diabetes. Since rs174576, rs174548, rs174550 and rs174583 were in strong LD with the tag SNP rs174547,
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similar significant results were found. Two other studies conducted in Caucasians [13] and Asians [15]
have reported SNP of rs174547 in FADS1 and rs174576 in FADS2 were in high LD (r2 ≥ 0.8).
Several earlier studies investigating healthy individuals have also shown that HDL-C
concentration can be modified by rs174547 C allele in Japanese [14] and Koreans [26], and by rs174547 C
allele and rs174550 T allele of FADS1 in people of Han Chinese decent [16]. The frequency of rs174547 C
allele in our investigation was 0.418, 0.458 in the HapMap Chinese population (Table 2), and 0.31–0.51
in Japanese, Mongolians and Caucasians [11,14]. Furthermore, a genome-wide association study
recruiting 19,840 European participants [11] found the minor C allele to be associated with reduced
HDL-C (p = 2.0 × 10−12) and increased triglyceride (p = 2.0 × 10−14). In that study, the authors
measured RNA expression in over 39,000 transcripts from 957 human liver tissues. Performing
expression quantitative trait locus analyses, they found the major T allele corresponded to the higher
transcript levels (p value (FADS1) = 5.0 × 10−35, p (FADS3) = 1.0 × 10−8). Together, these findings
show that SNP of rs174547 impacts both HDL-C levels and mRNA abundance of FADS1, suggesting
that rs174547 SNP is either functional or in LD with a functional SNP affecting expression or activities
of the FADS1.
Epidemiological studies have previously estimated D5D and D6D activities using PUFA
product-to-precursor ratios. Our study found a reverse relationship between carriers of C alleles of
FADS1 rs174547 and ratios of 20:4 (n-6)/20:3 (n-6) and 18:3 (n-6)/18:2 (n-6) as D5D and D6D desaturase
activities as well as 20:4 (n-6)/18:2 (n-6) and 20:5 (n-3)/18:3 (n-3) as n-6 and n-3 pathway activities.
Our findings were also confirmed by recent findings of a negative association between rs174547 C allele
and reduced desaturase activities or long chain PUFA levels in Dutch [27], in Europeans participating
in the HELENA study [24], in Caucasians and Asians participating in Toronto Nutrigenomics and
Health study [15] and in elderly Japanese [28]. Although none of these studies directly analyzed
desaturase activities, their findings suggest that the C allele of rs174547 may be related to insufficient
endogenous conversion of PUFA from their precursors via D5D or D6D.
The biological mechanism underlying how FADS genetic variations interact with desaturase
activities or PUFAs on HDL-C concentrations remains unclear. It is possible that C alleles of FADS1
rs174547 may impair desaturases leading to low yields of n-6 and n-3 long chain PUFAs such as 20:4n-6
and 20:5n-3. Furthermore, PUFAs are also known as ligands for peroxisome proliferator activating
receptorα,and they might modulate HDL-C metabolism by regulating expression of lipoprotein lipase
and apolipoprotein A-I [29] A-II [30] and C-III [31].
This study found D5D activity was significantly correlated and D6D was marginally with
HDL-C levels, but FADS1 rs174547and FADS2 rs2727270 polymorphisms were not, after adjusting for
confounding factors. Measurements of plasma n-6 or n-3 PUFA concentrations status represent overall
status of PUFA derived from both endogenous synthesis of PUFA via desaturation and elongation
as well as exogenous dietary consumption. Although there is evidence that genes for these steps can
be regulated by dietary PUFA, the degree to which dietary regulation of longer chain PUFA levels in
tissues through changes in expression of desaturase and elongase genes is unclear. Thus, a study based
on a larger diabetic sample size is needed to further explore possible interaction between dietary intake
of PUFA and genetic variations in FADS affecting lipoprotein metabolism. Environmental exposure
from diet and smoking is known to impinge on cardiovascular metabolic traits [32]. One study explored
the relationship between FADS1/FADS2 SNPs and lipoprotein concentrations in two genetically
similar Asian ethnic groups-Japanese (n = 21,004) and Mongolia (n = 1203) with distinctly different
lifestyles [14]. That study found a relationship between C alleles of FADS1 rs174547 and reduced
HDL-C and triglyceride levels in Japanese, but not in Mongolians. Substantial higher plasma n-3 PUFA
and higher n-3/n-6 PUFA ratio was observed in Japanese [33] due to the fact that Japanese habitually
consume large amounts of fish while Mongolians mainly consume livestock products, which may
partly explain the inconsistent impact of rs174547 on blood lipids between these two groups [14].
Hellstrand et al. [10] reported an association between high 18:3n-3/18:2n-6 ratio and 0.04 mmol/L
and 0.02 mmol/L higher HDL-C in 4635 Swedish individuals with CC genotype (p = 0.046) and TC
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genotype (p = 0.02), but not in those with TT genotype (p = 0.96). Their study results indicate that
intake levels of n-3/n-6 PUFA modify the associations between genetic variation in FADS and HDL-C.
In this study, we did not use multiple test correction to adjust significance of p value. While it
would be ideal if we could use multiple testing correction to ensure robustness of our analysis, it may
be limited in the case of this study because the hypotheses tested in this study were tested by analyses
of the a priori, not post hoc, and because we had many comparisons to perform, it would render ideal
p value indication of significance too small to be achieved. Our study is limited in that our sample
was small and our results may not be generalized to diabetes populations of other ethnicities. Future
studies need to increase sample sizes of diabetes patient groups and include a healthy controls in
order to better examine the relative impacts of FADS genetic polymorphisms as well as PUFA status
on dyslipidemia in diabetes and healthy subjects.
5. Conclusions
In conclusion, FADS1 rs174547 and FADS2 rs2727270 genotypes were significantly correlated with
decreased HDL-C concentrations, and D5D /D6D activities as estimated as 20:4(n-6)/20:3 (n-6) and
18:3 (n-6)/18:2 (n-6) in a linear pattern in patients with type 2 diabetes. The results of our multiple
variable regression analysis also further revealed that higher HDL-C status levels were positively
correlated with higher D5D and marginally with D6D activities, but not with the polymorphisms of
FADS1 rs174547and FADS2 rs2727270. Future studies with greater sample sizes are needed to confirm
this finding and further explore whether desaturase activities or PUFA status could interact with FADS
genetic variants to affect lipid metabolism or cardiovascular disease development in type 2 diabetes
patients. The understanding of the interaction between environmental modifiers and genetic variants
may facilitate future development of preventative strategies for public health genomics and counseling
or treatment approaches for personalized medicine.
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